These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1897 related items for PubMed ID: 7595699

  • 1. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 2. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G.
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [Abstract] [Full Text] [Related]

  • 3. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V, Schrappe M, Aricó M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig WD, Basso G, Masera G, Riehm H.
    J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
    [Abstract] [Full Text] [Related]

  • 4. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H.
    Klin Padiatr; 1998 Aug; 210(4):192-9. PubMed ID: 9743952
    [Abstract] [Full Text] [Related]

  • 5. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

  • 6. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies.
    Vecchi V, Aricò M, Basso G, Ceci A, Madon E, Mandelli F, Masera G, Massimo L, Pession A, Zanesco L.
    Cancer; 1993 Oct 15; 72(8):2517-24. PubMed ID: 8402470
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V.
    J Clin Oncol; 2008 Jan 10; 26(2):283-9. PubMed ID: 18182669
    [Abstract] [Full Text] [Related]

  • 8. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.
    Leukemia; 2013 Jul 10; 27(7):1497-503. PubMed ID: 23407458
    [Abstract] [Full Text] [Related]

  • 9. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME.
    J Clin Oncol; 1998 Mar 10; 16(3):920-30. PubMed ID: 9508174
    [Abstract] [Full Text] [Related]

  • 10. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, Rondelli R, De Rossi G, Lo Nigro L, Porta F, Santoro N, Indolfi P, Basso G, Conter V, Aricò M, Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Haematologica; 2001 May 10; 86(5):478-84. PubMed ID: 11410410
    [Abstract] [Full Text] [Related]

  • 11. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
    Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G, Associazione Italiano Ematologia Oncologia Pediatrica.
    J Clin Oncol; 2001 Mar 01; 19(5):1297-303. PubMed ID: 11230471
    [Abstract] [Full Text] [Related]

  • 12. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H, Kawakami K, Ayukawa H, Akiyoshi K, Kamizono J, Tamai Y, Kinukawa N, Okamura J.
    Med Pediatr Oncol; 2001 Jul 01; 37(1):10-9. PubMed ID: 11466717
    [Abstract] [Full Text] [Related]

  • 13. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R.
    Cancer; 2000 Jan 01; 88(1):205-16. PubMed ID: 10618625
    [Abstract] [Full Text] [Related]

  • 14. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
    Falletta JM, Shuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, Patterson R, Foreman E, Vietti TJ.
    Leukemia; 1992 Jun 01; 6(6):541-6. PubMed ID: 1602793
    [Abstract] [Full Text] [Related]

  • 15. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
    Cherlow JM, Steinherz PG, Sather HN, Gaynon PS, Grossman NJ, Kersey JH, Johnstone HS, Breneman JC, Trigg ME, Hammond GD.
    Int J Radiat Oncol Biol Phys; 1993 Dec 01; 27(5):1001-9. PubMed ID: 8262820
    [Abstract] [Full Text] [Related]

  • 16. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
    Aricò M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, Barisone E, Poggi V, De Rossi G, Locatelli F, Micalizzi MC, Basso G, Masera G.
    Blood; 2002 Jul 15; 100(2):420-6. PubMed ID: 12091331
    [Abstract] [Full Text] [Related]

  • 17. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Iyer R, Backstrom L, van Eys J, Harris M.
    J Clin Oncol; 1993 May 15; 11(5):839-49. PubMed ID: 8487048
    [Abstract] [Full Text] [Related]

  • 18. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
    Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD.
    J Clin Oncol; 1993 Mar 15; 11(3):520-6. PubMed ID: 8445427
    [Abstract] [Full Text] [Related]

  • 19. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C, Hartmann R, Fengler R, Schober S, Arlt I, Loewke M, Henze G.
    Blood; 1994 Jun 15; 83(12):3468-72. PubMed ID: 8204875
    [Abstract] [Full Text] [Related]

  • 20. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
    Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA.
    Cancer; 1998 Feb 01; 82(3):600-12. PubMed ID: 9452280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 95.